ClinicalTrials.gg
RecruitingNCT06195228Updated Aug 14, 2025

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

A Phase 4 interventional study of dabrafenib plus trametinib with or without PD-1 antibody and entrectinib or larotrectinib with or without anti-PD-1 antibdoy in Advanced Thyroid Cancer Patients Who Received Target Therapy, sponsored by Fudan University. Recruiting at 8 sites in China. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Fudan University · Phase 4, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Registered 3 years 11 months after the study started (first participant enrolled Jan 2020, registered Dec 2023).
  • Started Jan 2020; still recruiting 6 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
800
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Thyroid Neoplasms by Fudan University — 11 open to participants now, 11 under way, 2 of them phase 3. Thyroid Neoplasms · Fudan University.

Planned enrollment
Largest of 14
800 · median 66
Started
2020
with 3 others
Phase 4
Only one
of the 17
Primary completion
2026-12
later than 1 of 10 live
Registered
8th of 17
by date

Among the 17 studies in Thyroid Neoplasms by Fudan University, this one has the largest planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2020, is the only one in phase 4, reaches primary completion later than 1 of the 10 other live ones, and was the 8th registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

11 of the 17 studies in Thyroid Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Thyroid Neoplasms by Fudan University, or all of them as a file.
02

Study summary

This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer.

The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected.

The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.

Read the detailed description

see:Arms and Interventions

03

Conditions studied

  • Advanced Thyroid Cancer Patients Who Received Target Therapy

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients volunteered to participate in this study and signed ;
  2. Each center can be enrolled in patients who meet the age of their own practice range, regardless of gender ;
  3. diagnosed locally advanced or recurrent / thyroid cancer that cannot undergo radical surgery meets one of the following requirements:

    1. Radioiodine- differentiated thyroid cancer (RAIR-DTC);
    2. Differentiated thyroid carcinoma not suitable for iodine therapy;
    3. Medullary thyroid carcinoma (MTC);
    4. poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC);
  4. Thyroid-related pathogenic or therapeutic target gene detection was performed before enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Patients who are participating in clinical trials of other drugs;
  2. There is evidence that the patients are pregnant or lactating;
  3. Other situations that are not suitable for inclusion in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Radioiodine-refractory differentiated thyroid cancer

    advanced or metastatic thyroid cancer patients who are refractory to radioiodine treatment

    Drug: dabrafenib plus trametinib with or without PD-1 antibody · Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy · Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy · Drug: anlotinib or anlotinib plus anti-PD-1 antibody · Drug: lenvatinib plus anti-PD-1 antibody · Drug: Other Targets: precise treatment based on the target

  • Experimental
    Differentiated thyroid carcinoma not suitable for radioiodine therapy

    advanced or metastatic differentiated thyroid cancer patients who are not suitable for radio iodine therapy, for example, DTC patients with huge neck tumor but cannot receive the thyroid ectomy

    Drug: dabrafenib plus trametinib with or without PD-1 antibody · Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy · Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy · Drug: anlotinib or anlotinib plus anti-PD-1 antibody · Drug: lenvatinib plus anti-PD-1 antibody · Drug: Other Targets: precise treatment based on the target

  • Experimental
    Medullary thyroid cancer

    patients with advanced or metastatic medullary thyroid cancer

    Drug: dabrafenib plus trametinib with or without PD-1 antibody · Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy · Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy · Drug: anlotinib or anlotinib plus anti-PD-1 antibody · Drug: lenvatinib plus anti-PD-1 antibody · Drug: Other Targets: precise treatment based on the target

  • Experimental
    High-grade or poorly differentiated thyroid cancer

    patients with advanced or metastatic High-grade or poorly differentiated thyroid cancer

    Drug: dabrafenib plus trametinib with or without PD-1 antibody · Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy · Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy · Drug: anlotinib or anlotinib plus anti-PD-1 antibody · Drug: lenvatinib plus anti-PD-1 antibody · Drug: Other Targets: precise treatment based on the target

  • Experimental
    Anaplastic thyroid cancer

    patients with anaplastic thyroid cancer

    Drug: dabrafenib plus trametinib with or without PD-1 antibody · Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy · Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy · Drug: anlotinib or anlotinib plus anti-PD-1 antibody · Drug: lenvatinib plus anti-PD-1 antibody · Drug: Other Targets: precise treatment based on the target

Interventions

  • Drugdabrafenib plus trametinib with or without PD-1 antibody

    advanced thyroid cancer patients who harbor BRAF V600E mutation

  • Drugentrectinib or larotrectinib with or without anti-PD-1 antibdoy

    advanced thyroid cancer patients who harbor NTRK mutation

  • Drugpralsetinib or selpercatinib with or without anti-PD-1 antibdoy

    advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.

  • Druganlotinib or anlotinib plus anti-PD-1 antibody

    For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown

  • Druglenvatinib plus anti-PD-1 antibody

    Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation

  • DrugOther Targets: precise treatment based on the target

    Advanced thyroid cancer patients who had other treatment targets not included above

This study also gives LenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., EntrectinibStudies of EntrectinibEntrectinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate(ORR)

    Complete remission rate+ partial remission rate

    Time frame: up to approximately 3 years

Secondary outcomes

  1. Duration of Response(DOR)

    Time from the date of first partial remission or complete remission to the date of disease progression, or death of any cause, or date of lost follow-up, whichever comes first, otherwise subject data were censored at time last known disease free.

    Time frame: up to approximately 3 years

  2. Disease Control Rate(DCR)

    Complete remission rate+ partial remission rate+stable disease rate

    Time frame: up to approximately 3 years

  3. Time to response(TTR)

    Time from the initiation of the treatment to the first remission

    Time frame: up to approximately 3 years

  4. Progression Free Survival(PFS)

    Time from the date of enrollment to of disease progression, or death of any cause, or date of lost follow-up, whichever comes first, otherwise subject data were censored at time last known disease free.

    Time frame: up to approximately 3 years

  5. Overall survival(OS)

    Time from the date of enrollment to data of death from any cause, or date of lost follow-up, whichever comes first, and otherwise censored at time last known alive.

    Time frame: up to approximately 3 years

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2020 (actual). Primary completion is estimated for Dec 2026, 83 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2023
First posted
Jan 8, 2024
StartActual
Jan 1, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06195228
Lead sponsor
Fudan University
Collaborators
Peking Union Medical College Hospital, Shanxi Province Cancer Hospital, Henan Cancer Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Zhejiang Cancer Hospital, The Affiliated Hospital of Inner Mongolia Medical University, Ruijin Hospital, Fujian Cancer Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Shanghai 6th People's Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 10th People's Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Changhai Hospital, Tianjin Medical University Cancer Institute and Hospital, Jiangsu Cancer Institute & Hospital, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hunan Provincial People's Hospital, Dalian Friendship Hospital Affiliated to Dalian Medical University, The Third Affiliated Hospital of Soochow University, Sun Yat-sen University, Liaoning Cancer Hospital & Institute, Sir Run Run Shaw Hospital
Responsible party
Ji Dongmei (Associated Professor, Fudan University) — Principal investigator
First posted
Jan 8, 2024
Start date
Jan 1, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 14, 2025

Study contacts

Dongmei Ji, M.D
Contact
jidongmei2000@hotmail.com
021-64175590 ext. 83650
Dongmei Ji, M.D
principal investigator · Fudan University
Yu Wang, M.D
principal investigator · Fudan University
Qinghai Ji, M.D
principal investigator · Fudan University
Yansong Lin, M.D
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Entrectinib

Start the discussion